<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04615767</url>
  </required_header>
  <id_info>
    <org_study_id>UVittorio1</org_study_id>
    <nct_id>NCT04615767</nct_id>
  </id_info>
  <brief_title>D-chiro-inositol Increases Androgens and Reduces Estrogens in Human Serum</brief_title>
  <official_title>D-chiro-inositol, a Putative Aromatase Inhibitor, Increases Androgen and Reduces Estrogen Levels in Serum of Male Volunteers. A Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGUNCO Obstetrics and Gynecology Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGUNCO Obstetrics and Gynecology Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot study is to test the effect of a 30 day-D-chiro-inositol oral treatment&#xD;
      on a set of clinical parameters (mainly sex hormones) in a group of male volunteers selected&#xD;
      by their age and BMI to investigate if D-chiro-inositol acts as an aromatase inhibitor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label clinical trial with a dietary supplement carried out in male volunteers&#xD;
      selected by their age and BMI. The aim is to test the effect of oral daily treatment with 1 g&#xD;
      D-chiro-inositol for 30 days on some clinical parameters, to see if D-chiro-inositol acts as&#xD;
      an aromatase inhibitor. Testosterone, estradiol, Testosterone/Estradiol ratio,&#xD;
      Dehydroepiandrosterone sulfate, Estrone, glycemia and insulinemia (with calculation of HOMA&#xD;
      index), follicle-stimulating hormone, Luteinizing hormone, D-chiro-inositol and Myo-inositol&#xD;
      serum concentrations have to be determined before and after D-chiro-inositol administration.&#xD;
&#xD;
      We wish to evaluate if this treatment for one month is able to change the sexual hormone&#xD;
      levels, increasing androgens and decreasing estrogens. Furthermore, we wish to control the&#xD;
      safety profile of D-chiro-inositol, a well-known molecule, different from the classic&#xD;
      aromatase inhibitors. We think that our pilot study can open up new perspectives of research&#xD;
      and therapeutic applications for this many-sided molecule.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Actual">December 16, 2020</completion_date>
  <primary_completion_date type="Actual">December 6, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Ten male volunteers are treated daily with 1 g D-chiro-inositol for 30 days (2 capsules containing 500 mg each, twice a day). The serum levels of the detected parameters at the end of treatment are compared to the values found in the volunteers at the baseline, used as controls. Parameters under analysis: Testosterone/Estradiol ratio, Testosterone, dehydroepiandrosterone, estradiol, estrone, glycemia and insulinemia with Homeostatic Model Assessment for Insulin Resistance (HOMA) index, follicle stimulating hormone, luteinizing hormone, D-chiro-inositol and myo-inositol.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of the Testosterone/Estradiol ratio in serum</measure>
    <time_frame>Thirty days</time_frame>
    <description>Assessment of the D-Chiro-Inositol treatment to increase the Testosterone/Estradiol ratio by detecting these physiological parameters in serum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dehydroepiandrosterone sulfate</measure>
    <time_frame>Thirty days</time_frame>
    <description>Detecting the serum levels of Dehydroepiandrosterone sulfate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estrone</measure>
    <time_frame>Thirty days</time_frame>
    <description>Detecting the serum levels of Estrone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostatic Model Assessment for Insulin Resistance (HOMA) Index</measure>
    <time_frame>Thirty days</time_frame>
    <description>Detecting glycemia and insulinemia</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Low Serum Testosterone Levels in Man</condition>
  <arm_group>
    <arm_group_label>D-chiro-inositol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers are orally administered with 1 g D-chiro-inositol per day (two doses in capsules of 500 mg each, one in the morning and the other one in the evening) for thirty days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>D-chiro-inositol</intervention_name>
    <description>as described previously</description>
    <arm_group_label>D-chiro-inositol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) range is between 22 and 34 kg/m2, in order to include subjects&#xD;
             with normal weight, overweight and obese. Subjects with altered glycemia or hormonal&#xD;
             status due to age or weight were enrolled in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Men with poor general health were excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Monastra</last_name>
    <role>Principal Investigator</role>
    <affiliation>Systems Biology Group Lab, Rome, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Alma Res</name>
      <address>
        <city>Rome</city>
        <zip>00198</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Testosterone</keyword>
  <keyword>DHEAS</keyword>
  <keyword>Estradiol</keyword>
  <keyword>Estrone</keyword>
  <keyword>HOMA index</keyword>
  <keyword>D-chiro-inositol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

